Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ]: Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012
Mon, August 20, 2012
Sat, August 18, 2012
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ]: Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ]: Market Wire
Head of European Operations

Transition Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. -canaccord-genuity-annual-growth-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Transition Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Transition Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

[ ]

TORONTO, Aug. 13, 2012 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH, NASDAQ: [ TTHI ]) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the Canaccord Genuity Annual Growth Conference on Thursday, August 16th, 2012 at 2:00 p.m. Eastern Time at the Intercontinental Boston Hotel in Boston, Massachusetts.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead product is ELND005 (AZD-103) for the treatment of Alzheimer's disease and Transition also has an emerging pipeline of innovative preclinical and clinical drug candidates. The other drugs in the pipeline that the Company is developing are for anti-inflammatory and metabolic indications. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit [ www.transitiontherapeutics.com ].

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.



[ Back to top ]